AKT is a serine/threonine protein kinase that regulates a major pro-survival signaling network and affects a variety of cellular processes including proliferation, survival, and protein translation, 1 which makes AKT a potential therapeutic or preventative target for cancer. 2 Overexpression of AKT has been correlated with the development and metastasis of various cancers. [3] [4] [5] Activation of AKT disturbs the balance of cell survival and apoptosis by promoting pro-survival transcription factors (CREB and NF-KB) and inhibiting the FOXO3a pro-apoptotic transcription factor. [6] [7] [8] FOXO3a has a pivotal role in both oncogenesis and tumor suppression. 9 Loss of FOXO3a has been observed in various cancers, and its cellular localization and phosphorylation status are considered to be prognostic factors for breast, 10 prostate, 11, 12 bladder, 13 and ovarian cancer. 14 
Activated
FOXO3a triggers cell-cycle arrest and apoptosis through expression of genes necessary for cell death, 15 including Fas ligand (FasL), tumor necrosis factor-related apoptosis-inducing ligand (TRAIL), and Bim. 16 Overexpression of FOXO proteins induces apoptosis in cells of various tissue types and possesses tumor-suppressor functions. 17 Together, these studies suggest that FOXO3a functions as a tumor suppressor, and therefore may serve as either a direct or indirect target for cancer therapy. 18 Prostate apoptosis response-4 (Par-4), also known as PAWR, is a tumor-suppressor protein that is reported to cause apoptosis in cancer cells 19, 20 by activating both intrinsic and extrinsic pathways. 21 Par-4 is expressed in diverse normal and cancerous cell types and tissues, and resides in both the cytoplasm and the nucleus. Downregulation of Par-4 is considered to be critical for tumorigenesis as it is downregulated in various human cancers including prostate cancer (CaP). 22 Par-4 knockout mice spontaneously develop tumors in various organs 21 and exhibit prostatic intraepithelial neoplasia. 23 In order for endogenous levels of Par-4 in normal and cancer cells to cause apoptosis, an additional stimulus is required. [24] [25] [26] CaP is the third leading cause of cancer-related death in men in the United States. 27 Most patients initially respond to hormone ablation therapy. However, some patients eventually become refractory to such treatments, having developed what is known as castration-resistant prostate cancer (CRPC). 28 Par-4 modulation has tremendous therapeutic potential and, indeed, genetic or pharmacological strategies to induce Par-4 expression are currently under investigation for cancer prevention or treatment. 29 Withaferin-A (WA) is a natural bioactive compound derived from the roots and stems of Withania somnifera, which is cytotoxic in several cancer cell lines. 30, 31 Our previous reports confirmed that Par-4 is a critical downstream target for WA treatment to execute its anticancer effect against CRPC. 32 Dissecting signaling cascades upstream of Par-4 might allow us to identify potential therapeutic targets that can restore Par-4 function in CRPC cells.
In the present study, we demonstrate that Par-4 is one of the downstream transcriptional targets of FOXO3a that executes pro-apoptotic function in CRPC cells. FOXO3a directly interacts with the Par-4 promoter and activates and initiates caspase-mediated cell death upon WA treatment. Small molecules such as WA can restore the FOXO3a and Par-4 signaling axis and apoptosis, which could be an attractive target for treatment of CRPC.
Results

WA inhibits AKT signaling and induces Par-4 activation in AR-null CRPC cells. Inhibition of pAKT expression was evident in WA-treated cells (PC-3 and DU-145) and induced
Par-4 expression in a time-and dose-dependent manner (data not shown) by western blot analysis (Supplementary Figure S1A ). GSK-3β acts as a downstream effector of AKT that executes AKT-induced cell growth, proliferation, and survival in many cancer types, including CaP cells; hence, we analyzed GSK-3β expression in CaP cells. 33, 34 A decrease in phosphorylated GSK-3β expression was observed in WA-treated CRPC cells (Supplementary Figure  S1A ) in a dose-(data not shown) and time-dependent manner similar to that of Par-4 induction (Supplementary Figure S1A ). Consistently, upregulation of Par-4 transcription (2.5-to 7-fold) and promoter activation (2-to 4-fold) was observed in both CRPC cell types (Supplementary Figure  S1B and C). Inhibition of AKT or induction of Par-4 by WA in both CRPC cell lines resulted in WA-induced dose-dependent growth inhibition in both cell lines (Supplementary Figure S1D ). Together, these results reveal that WA inhibits AKT activity and induces Par-4, which correlates with WA-induced cytotoxicity in CRPC cells.
Inhibition of AKT negatively regulates Par-4 function in AR-null CRPC cells. To elucidate the functional role of Par-4 in response to AKT signaling, we either transiently transfected myr-AKT or stably transfected total AKT into CRPC cells and studied AKT-mediated Par-4 function in response to WA treatment. Cell viability assays suggest that AKT-overexpressed cells grow much faster (~1.2-fold in PC-3 (data not shown) and 1.5-fold in stable AKT/DU-145) than vector-transfected CRPC cells (Figures 1a and b ). WA treatments significantly overcome AKT-mediated growth induction in both PC-3 and DU-145 cells (Figures 1a and b) .
WA treatment induced Par-4 in vector-transfected cells; however, WA partially rescues Par-4 expression in AKT-overexpressed cells (Figure 1c ). However, a higher concentration of WA completely downregulates pAKT expression and upregulates Par-4 function in CRPC cells (data not shown). Similar results were found in stably overexpressed AKT/DU-145 cells ( Figure 1e ). However, WA treatment restored Par-4 mRNA expression ( Figure 1d ) and partially promoter activity in PC-3 cells ( Figure 1f ).
Molecular link between FOXO3a
and Par-4 in AR-null CRPC cells. WA inhibited pFOXO3a(ser253) expression and allowed total FOXO3a accumulation in CRPC cells. Endogenous FOXO3a activation levels in these cells were determined by analyzing the expression of p27, which is a known downstream target of FOXO3a. Increased timedependent expression of p27 suggested that WA induced FOXO3a function in CRPC cells (Figure 2a ). No alteration in 14-3-3 expression was seen in WA-treated CRPC cells (Figure 2a ), suggesting that FOXO3a accumulation in the nucleus is not due to inhibition of 14-3-3. FOXO3a transcription is upregulated by 4-to 5-fold compared with vehicletreated control following WA treatment of both PC-3 and DU-145 cells ( Figure 2b ).
Higher levels of FOXO3a transcription and accumulation of FOXO3a expression were seen in both nuclear and cytoplasmic compartments in WA-treated cells as compared with vehicle-treated PC-3 cells ( Figure 2c ). A concomitant nuclear accumulation of Par-4 was also seen in WA-treated cells (Figure 2c ). In immunofluorescence studies, as expected, WA-treated cells exhibited co-localization of both FOXO3a and Par-4 in the nucleus, signifying that to execute their proapoptotic function both proteins should be localized in the nucleus (Figure 2d ). In proximity ligation assays, which are used to visualize nuclear co-localization events, 35 costaining of WA-treated CRPC cells with FOXO3a and Par-4 antibodies showed an appearance of red dots in the nucleus, which implies the close proximity of the two proteins. In control cells, no distinct red dots appeared (Figure 2e Figure S2A ). Furthermore, immunofluorescence data revealed that WA fails to induce Par-4 expression as well as nuclear localization in CT-FOXO3a-transfected cells, suggesting that Par-4 transactivation was compromised by CT-FOXO3a (Supplementary Figure S2B ). Inhibition of Par-4 promoter activity was seen in CT-FOXO3a-transfected cells when compared with controls and WA fails to rescue Par-4 activation in CT-FOXO3a cells (Supplementary Figure S2C ). CT-FOXO3a-transfected cells showed resistance to WA treatment in cell viability assays, suggesting that FOXO3a transactivation may be required for Par-4-mediated cytotoxicity in CRPC cells (Supplementary Figure S2D ). Overall, these results suggest that Par-4 signaling is downstream of FOXO3a signaling, and FOXO3a activation is essential for Par-4 function in CRPC cells. To confirm further FOXO3a mediated Par-4 regulation, we over expressed FOXO3a, which activated significantly Par-4 promoter, however sequential deletion of FOXO3a binding sites in each deletion constructs showed a gradual loss of Par-4 promoter activity (Figure 5b ).
To confirm whether FOXO3a directly binds to Par-4 promoter, DNA pull-down assay was performed. Cells that expressed TM-FOXO3a showed significant binding to the oligonucleotides containing wild-type FOXO3a-binding sequences corresponding to the Par-4 promoter binding sites, while DBM-FOXO3a failed to bind. These data provide further evidence suggesting that FOXO3a has potential binding sites available in the Par-4 promoter (Figure 5c ). We next performed chromatin immunoprecipitation (Ch-IP) assays to determine the FOXO3a occupancy on the Par-4 promoter. As demonstrated in Figure 5d , an increased binding of FOXO3a to this Par-4 promoter region is consistent with the DNA pull-down results. Overall, all three experiments confirm that FOXO3a transcriptionally regulates Par-4 expression in CRPC cells.
Xenograft models: Overexpression of AKT induces aggressive tumor growth and WA overrides AKT-mediated growth and restores Par-4 function. CRPC cells that stably expressed AKT/DU-145 and/or pCMV/ DU-145 were implanted subcutaneously into the right flank of nude mice and tumors were allowed to grow. Tumor growth was monitored once a week. When the tumor volume reached 50 mm 3 , animals were assigned to one of the two groups. One group received sesame oil or WA (4 mg/kg/body weight) by oral gavage for 4 weeks. Intriguingly, AKToverexpressing tumors showed 2-to 3-fold faster growth than pCMV-expressing CRPC tumors (Figure 6a ). Oral administration of WA significantly reduced AKT-induced xenograft tumor growth. H&E staining in AKToverexpressing tumors exhibited an increase in the mitotic index (3-to 4-fold) as compared with pCMV-transfected tumor samples ( Figure 6b) . Similarly, we found that WA-treated both tumors (pCMV and AKT transfected) showed a marked induction of necrosis (10-15%) as compared with vehicletreated tumor tissues. Immunohistochemistry of tumor sections revealed high expression as well as nuclear localization of pAKT followed by low levels of Par-4 in sections from AKT-overexpressing tumors as compared with pCMV-expressing tumors. Increased and intense nuclear localization of Par-4 and decreased expression of AKT and pAKT were observed in WA-treated AKT-overexpressing tumors, suggesting an AKT-Par-4 axis. By contrast, pCMV tumor sections derived from WA-treated animals showed less expression of activated AKT and more nuclear-localized Par-4 ( Figure 6c ).
To confirm that activated AKT negatively regulates Par-4 function and to validate our in vitro and in vivo findings, we performed an immunohistochemical analysis of pAKT and Par-4 expression on human prostate tissue microarrays (TMAs). The TMA contains normal benign or hyperplasia samples (BPH) (n = 12) and prostate tumor samples of different grades (n = 32). pAKT expression was evident in 7/16 (43%) grade I (Gleason 6) and II (Gleason 7) tumor samples and in 68.75% of grade III (Gleason 8-10) tumor samples (11/16 ). On the other hand, in BPH the expression of pAKT was confined to the basal and secretory layers of the cytoplasm. Similarly, nuclear Par-4 expression was detected in the basal layers of BPH, and cytoplasmic accumulation was seen in secretory cells. Interestingly, in a variety of tumor stages, Par-4 was localized in the cytoplasm, indicating that the pro-apoptotic machinery was compromised in tumor samples ( Figure 6d ).
Discussion
Oncogenic activation of AKT regulates many signaling cascades that control cell proliferation, survival, growth, inhibition of apoptosis, and resistance to current drug therapies. 36, 37 Here, we demonstrate that AKT activation inhibits the pro-apoptotic function of Par-4 by suppressing FOXO3a activation in CRPC cells. In addition, the results revealed that Par-4 is one of the downstream targets of FOXO3a and is dependent on FOXO3a to activate its proapoptotic functions in CRPC cells.
In our results, we found that WA inhibits AKT activation by inhibiting phosphorylation at Ser 473 , which results in downregulated phosphorylation of its downstream substrate GSK-3β, confirming the suppression of AKT kinase activity. AKT phosphorylates Par-4 and sequesters it in the cytosol, thereby preventing its pro-apoptotic function. 38 In contrast, PKA phosphorylates Par-4 at T163, which activates the pro-apoptotic functions of Par-4 to induce apoptosis. 19 We delineated the molecular circuit between AKT and Par-4 by either transiently or stably overexpressing AKT and measuring Par-4 expression and function in CRPC cells. AKT-overexpressed CRPC cells proliferated at a higher rate by transcriptionally downregulating Par-4 expression and function. The cell viability and apoptotic assays suggested that treatment with WA partially rescued AKT-mediated resistance to apoptosis in CRPC cells by upregulating Par-4 function. Similar studies have shown that by inhibiting AKT with siRNA, LY294002 or KD-AKT, Par-4 mediated pro-apoptotic function was rescued in CaP cells. 38 In our studies, inhibition of AKT activation correlates with concomitant induction of FOXO3a and Par-4, so we investigated the molecular link between FOXO3a and Par-4 in CRPC cells. Activated AKT phosphorylates FOXO3a at Thr 32 , Ser 253 , or Ser 315 residues and inhibits pro-apoptotic activity such as cell-cycle arrest by downregulating p27, GADD45, and BIM expression. [39] [40] [41] Loss of FOXO3a function may lead to the suppression of apoptosis 42 and failure of cell-cycle arrest, which may lead to tumorigenesis. 41 The 43 and in leukemia cells. 44 These results concur with our findings that activation of FOXO3a induces pro-apoptotic function by triggering Par-4 function.
Similar results were achieved with DBM-FOXO3a-or CT-FOXO3a-overexpressed cells that fail to activate Par-4 reporter expression. The direct binding of FOXO3a to sites on the Par-4 promoter was further confirmed by sequentially deleting FOXO3a-binding sites, which fails to activate WAinduced Par-4 function in CRPC cells. FOXO3a is known to transactivate various pro-apoptotic genes. [41] [42] [43] 45 We have for the first time demonstrated that Par-4 is one of the downstream pro-apoptotic effectors in CRPC cells by sequentially deleting FOXO3a-binding sites in the Par-4 promoter. These results were similar to findings that FOXO3a activates Bim and induces apoptosis. 46 We further confirmed that inhibition of AKT triggers FOXO3a-mediated Par-4-induced cell death in xenograft models. Treatment with WA results in inhibition of AKT and induction of FOXO3a-dependent Par-4-mediated growth inhibition in vector-as well as in AKT-overexpressed tumors. To confirm the inverse relationship of pAKT and Par-4 expression in human prostate specimens, we performed immunohistochemistry analysis on human prostate TMAs. The results clearly suggested that Par-4 is expressed in BPH whereas pAKT expression was mostly localized in the cytoplasm. We also observed that pAKT is gradually overexpressed in grade-specific manner, whereas Par-4 was completely absent in the tumor specimens. More specifically, nuclear pAKT abrogated Par-4 nuclear localization in tumor tissues. We understand that the limited sample size used in these experiments limits our ability to come to a conclusion. Nevertheless, our results suggest that AKT activation downregulates Par-4 function in CaP, which could be a causative factor for CaP progression.
In conclusion, our findings demonstrate that WA efficiently inhibits growth and induces apoptosis in AR-null CRPC cells. WA promotes the nuclear accumulation of FOXO3a, and thus activates its target gene Par-4. These data provide evidence for FOXO3a-dependent transactivation of Par-4 gene activation, which is under tight regulation by AKT. Notably, these results confirm that the AKT/FOXO3a/Par-4 signaling axis can be attractive target for prevention or treatment of CaP.
Materials and Methods
Cell lines, antibodies, and reagent. Human prostate carcinoma cell lines, PC-3 and DU-145, were obtained from American Type Culture Collection and cultured (ATCC) and cultured according to the manufacturer instructions. No authentication was done by authors. Withaferin-A obtained from Nucleus Biopharma Inc. (Calbiochem, Billerica, MA, USA) was dissolved in dimethyl sulfoxide (DMSO), and the cells were treated with DMSO at a final concentration of 0.002%. The following antibodies obtained from Cell Signaling Technology (Danvers, MA, USA) were used for the immunoblotting: AKT, pAKT, FOXO3a, pFOXO3a, p27, 14-3-3, cleaved PARP, cleaved caspase-9, BCL2, and BAX. Antibodies for Par-4, pGSK-3β, 14-3-3, HA, GAPDH, β-actin, and tubulin, and secondary antibodies of anti-mouse, anti-goat, and anti-rabbit were purchased from Santa Cruz Biotechnology Cell proliferation assay. To confirm the viability of PC-3 and DU-145 cells, MTT assay was performed following the manufacturer's protocol. 47 Western blot analysis. The CaP cell lines were treated with the earlier mentioned WA concentrations for the different time points. Cell lysates were used for western blot analysis of the above-specified proteins. 48 Real-time quantitative PCR. Total RNA was isolated from DU-145, and PC-3 cell lines by Qiagen RNeasy Kit (Valencia, CA, USA), and 1 μg RNA was used for cDNA synthesis using the Applied Biosystems cDNA synthesis kit and amplified using SYBR Green supermix (Quiagen Inc, CA, USA). Quantitative RT-PCR was performed as previously published. 48 Immunofluorescence microscopy analysis. Fluorescence microscopy was performed on cells grown in 6-well plates containing sterile coverslips and these cells were treated with WA. Subsequently incubated with anti-FOXO3a and/or Par-4 antibody (1 : 500 dilutions) or isotype control antibody and then by fluorescent-tag-conjugated secondary antibodies, using the Nikon T1-Eclipse microscope. 49 PLA proximal ligation assay. PLA is a latest proteomics approach for detection of proteins, protein-protein interaction, and post-translational modifications (Olink Biosciences, Uppsala, Sweden). Cells were treated and fixed with anti-FOXO3a and anti-Par-4 antibodies together and allowed to generate rolling circle amplification (RCA) by using specific PLA probe sets. The oligonucleotide sequences were used to detect the proteins that are in close proximity and enzymatically joined to create RCA products. Such immobilized RCA products (RCPs) can be visualized by hybridization of fluorescently-labeled detection oligonucleotides to a sequence encoded in the DNA circle. The amplified RCA corresponds to the amount of oligonucleotides hybridized which produced a bright strong signal, distinguishable from the background in a fluorescence microscope. 50, 51 Apoptosis assay. Apoptosis assays were performed with the Annexin V-fluorescein isothiocyanate apoptosis kit-I (BD Pharmingen, San Diego, CA, USA) as described previously. 48 Transfection. Cells were plated at a density of 3 × 10 5 /well to achieve a confluence of ∼ 70% after 24 h. Cells were transfected with 1-2 μg of expression vector using Lipofectamine according to the manufacturer's instruction. Cells were incubated at 37°C, and the medium was replenished with fresh medium in the presence and/or absence of WA for additional 24 h before the cells were harvested.
Small interfering RNA. For silencing Par-4 and FOXO3a expression, cells were transiently transfected with 25 nM of Par-4-specific siRNA and 50 nM of FOXO3a-specific siRNA or control non-silencing (NS) siRNA (Santa Cruz Biotechnology). Cells were using siQuest transfection reagent (Mirus, Madison, WI, USA) following the manufacturer's protocol. 49 ELISA-based DNA-Protein interaction assay. Oligonucleotides representing FOXO3a binding site on the Par-4 promoter sequence were synthesized, and the strands were 5′-labeled using the terminal biotin (Integrated DNA Technologies, Coralville, IA, USA). The biotin-labeled sense strand was annealed to its complementary antisense strand and purified over a Sephadex G-50 column (Sigma-Aldrich). The ER alpha site promoter was used as the positive control. 9 The prepared nuclear extracts were incubated with Par-4 promoter regions, and oligos bearing FOXO3a-binding sites were utilized.
DNA pull-down assay. DNA fragment with a wild-type or mutant FOXO3a-binding site and with 5-biotin-labeled forward primers was used. The biotinylated probes were mixed with cell lysates transfected with TM-FOXO3a and DBM-FOXO3a, respectively. This was followed by the addition of streptavidinagarose beads (Invitrogen) with incubation for an additional 1 h. The streptavidinagarose beads were washed five times with the binding buffer and continued by the addition of SDS-sample buffer. This complex was subjected to immunoblotting with anti-HA antibody.
Cloning of the Par-4 promoter. The Par-4 sequence between +1 and − 2907 bps was utilized to generate two luciferase reporter plasmids with 5'-UTR +1 to − 2900 (2.9 KB) and without 5' UTR − 762 to 2900 bp (2.1 KB). Amplification of the Par-4 promoter fragment was done by PCR using primers specific for the region of interest. PCR was conducted using Phusion high fidelity PCR master mix (NEB, MA, USA). Amplified product was digested with restriction enzymes, Kpn1 and Xho1; and same sites were used to nick the reporter vector to get sticky ends and were utilized for ligation. Ligation mixture was transformed and screened using ampicillin selection. The plasmid DNA fragment encoding the Par-4 region in pGL3-Basic luciferase reporter vector (Promega, Madison, WI, USA) was validated by sequencing.
Chromatin immunoprecipitation. Ch-IP was performed as described in Cell Signaling ch-IP kit with some modifications. CaP cells over expressing FOXO3a were treated with formaldehyde (1%) for 10 min at 37°C to cross-link proteins to DNA. Soluble chromatin was subjected to overnight immunoprecipitation with anti-FOXO3a antibody. Following immunoprecipitation and elution, the eluent was heated to reverse the cross-link and DNA was isolated and subjected to amplification. PC-3 cells transfected with/without FOXO3a were also subjected to Ch-IP with the anti-FOXO3a antibody. The PCR products were resolved on a 1.5% agarose gel, stained with ethidium bromide.
Dual-luciferase reporter assay. To perform the dual-luciferase reporter assay, Par-4-luc promoter constructs and Deleted-Par-4 constructs (1-3 μg) and Renilla luciferase (100ηg) vectors were cotransfected using Lipofectamine 2000 (Invitrogen). The reporter assay was performed using the Dual-Luciferase Reporter Assay System from Promega. 49 Xenograft studies. All animals were housed under pathogen-free conditions, and experiments were performed in accordance with Institutional Animal Care and Use Committee approval, Texas tech university health sciences center, El Paso, Texas. Balb/c athymic nude mice (nu/nu) were purchased from the Jackson Laboratory (Bar Harbor, ME, USA) and used at 6-8 weeks of age. For tumor xenograft studies, pCMV/DU-145 or AKT/DU-145 cells (2.5 × 10 6 ) in a 50-μl final volume matrigel matrix were injected subcutaneously into separate flanks of the mouse (6-8 animals). The mice were monitored twice weekly, and tumor volumes were measured once a week.
Immunohistochemical analysis. Human Prostate cancer TMA (Cat no. PRC 961) was purchased from Pantomics (Richmond, CA, USA). Each slide has 48 cases from hyperplastic and cancer tissues with progressive Gleason scores and TNM stages in duplicates. For each grade, the TNM classification is provided in the product data sheet. PCa tissue array slide was stained with primary antibody for AKT, pAKT (ser473), Par-4, FOXO3a and pFOXO3a (ser253) followed by secondary antibody incubation, and was analyzed under a light microscope. The TMA slide was viewed and scored by a pathologist.
Statistical analysis. Data are represented as the mean ± standard errors mean (S.E.M.). Significant differences between the groups were determined using the unpaired Student's t-test (Po0.05). All statistical analyses were performed with GraphPad Prism 6.0a software (GraphPad Software Inc., La Jolla, CA, USA) or Microsoft Excel.
